Ivermectin has been given to people in Africa, Latin America and Asia billions of times through community-wide treatment campaigns against river blindness and lymphatic filariasis. These programs deliberately exclude pregnant women, yet because early pregnancy is often not apparent, many women have taken the drug without knowing they were carrying a child. This article explains what follow-up studies of those women found, what a major 2020 meta-analysis concluded, what animal data show, and why careful programs still choose to wait until after birth. In brief, the human data are reassuring but too limited to prove safety, and that gap is the reason the exclusion remains.

A drug from the soil and the scale of its use

Ivermectin is a semi-synthetic derivative of the avermectins, compounds produced by a bacterium, Streptomyces avermitilis, that the Japanese microbiologist Satoshi Ōmura isolated from a soil sample collected near a golf course in Shizuoka Prefecture in the 1970s. William Campbell's team at Merck then showed its potency against parasitic worms. The two shared the 2015 Nobel Prize in Physiology or Medicine. There is something fitting in the fact that one of the most useful antiparasitic medicines in history came from a teaspoon of ordinary earth. The created world holds remedies we are still learning to find and use wisely.

Since 1987 the manufacturer has donated ivermectin for onchocerciasis (river blindness), and later for lymphatic filariasis in parts of Africa, where it is given alongside albendazole and sometimes diethylcarbamazine. Doses are given once or twice a year to whole communities, usually by trained volunteers going house to house. In the United States, ivermectin tablets are approved for strongyloidiasis and onchocerciasis. They are not approved for use in pregnancy, and the label states that adequate, well-controlled studies in pregnant women have not been done.

Who is excluded, and how exposure still happens

Community programs typically exclude:

Pregnancy screening in these settings usually depends on asking the woman or on visible signs, not on laboratory tests. A woman in her first several weeks may not know she is pregnant, and she may not wish to say so to a neighbour acting as distributor. As a result, inadvertent exposure falls mostly in the first trimester, when the baby's organs are forming. That is the period of greatest theoretical concern, and it is also what has made these unplanned exposures scientifically informative.

What the human studies found

Several groups followed women who were later found to have been pregnant when they took a dose. The most cited studies are these:

In 2020 Nicolas, Maia, Bassat and colleagues, working with the Barcelona Institute for Global Health (ISGlobal), published a systematic review and meta-analysis in The Lancet Global Health. They pooled the available studies, which together covered fewer than a thousand exposed pregnancies, mostly in the first trimester. They found no statistically significant increase in miscarriage, stillbirth, congenital anomalies or other adverse outcomes. They also rated the evidence as low quality and concluded that it was insufficient to make conclusive statements about safety. The analysis reported no clear signal of harm, which is different from evidence that the drug is safe. The researchers took care to say so, and readers should too.

Why reassuring data are not yet enough

If no study has found harm, why not simply treat everyone? The answer lies in what these studies could and could not detect.

Animal studies add to the caution. In mice, rats and rabbits, ivermectin at high doses produced malformations, including cleft palate and limb deformities. These effects generally appeared at or near doses that were toxic to the mother, which are far above the single standard human dose of about 150 to 200 micrograms per kilogram. Animal results do not translate directly to people, but they are a reason not to dismiss the question.

There is also a biological reason for care. Ivermectin is kept out of the mammalian brain largely by P-glycoprotein, a transporter in the blood-brain barrier. Mice and dogs that lack functional P-glycoprotein are far more sensitive to ivermectin's neurotoxic effects. Some researchers have noted that this protective system is still maturing before birth, so the fetus may be less shielded than an adult. This is a plausible concern drawn from animal and mechanistic work. It has not been demonstrated as a harm in human pregnancies.

The deciding factor: treatment can usually wait

The strongest reason for the exclusion is practical. River blindness and lymphatic filariasis are chronic infections that develop over years. Missing one annual dose during pregnancy does little harm to the mother, and she can be treated after delivery. When a short delay costs the mother little, even a small, unquantified risk to the child is hard to justify.

From a pro-life perspective, this reasoning should be familiar. A pregnant woman carries a second patient, a child whose life has worth from its beginning and who cannot consent or speak for himself. Good medicine in pregnancy weighs the benefit to the mother against possible risk to the child. When the benefit can be safely postponed, waiting is an act of care. The exclusion reflects honest caution about what is not yet known, not a judgement that pregnant women matter less.

The balance may differ in other settings. Researchers are studying ivermectin given to whole communities to reduce malaria transmission, because mosquitoes that bite treated people die sooner. They are also studying it for community-wide scabies control. In those settings, leaving pregnant women out may reduce the effect on the community, and some scientists have argued for carefully designed pregnancy studies. These remain research questions. Neither use is an approved indication in pregnancy, and treating more people requires better pregnancy safety data, gathered with full informed consent.

If you took ivermectin before you knew you were pregnant

Women sometimes discover they were pregnant when they took a dose, whether in a community campaign or from a prescription. The available evidence is reassuring and does not suggest that a single standard dose is likely to have caused harm. Even so, the evidence cannot give a firm guarantee, so the sensible step is to tell your own physician or midwife. They can record the exposure, consider the timing, and fold it into ordinary prenatal care, including the routine anatomy ultrasound in mid-pregnancy. You have a right to understand what is and is not known, and a good clinician will explain it plainly.

Taking ivermectin on one's own during pregnancy, including veterinary products formulated for livestock, is a different matter. Animal formulations are concentrated, hard to dose accurately for a person, and may contain other ingredients. Wanting to protect your own family is admirable. In pregnancy, that duty is usually best served by a careful conversation with a physician who knows you, not by self-treatment.

Ivermectin passes into breast milk in small amounts, and the infant's estimated dose is low. Programs exclude women only in the first week after delivery, and most nursing mothers can be treated after that.

Key takeaway: Studies of women who took ivermectin unknowingly in early pregnancy have found no clear sign of harm, but those studies are too small to prove safety, so programs reasonably defer treatment until after birth.